Platelet-activating factor antagonism: A new concept in the management of regional myocardial ischemia-reperfusion injury

Journal of Investigative Surgery

Volumn 10, Issue 6, 1997, Pages 321-338

  Loucks, Eric B ^a   Symersky, Petr ^a   Qayumi, A Karim ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Heart; Ischemia reperfusion injury; Myocardial infarction; Oxygen derived reactive substances; PAF antagonists; Platelet activating factor

Indexed keywords

ENDOTHELIN; LEUKOTRIENE; REACTIVE OXYGEN METABOLITE; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; THROMBOXANE;

CARDIOVASCULAR FUNCTION; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEMODYNAMICS; MEDIATOR; MEDIATOR RELEASE; MORTALITY; NECROSIS; PATHOGENESIS; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SURVIVAL;

EID: 0031398932     PISSN: 08941939     EISSN: None     Source Type: Journal    
DOI: 10.3109/08941939709099596     Document Type: Review

References (164)

1. Wilcox RG, Olsson CG, Skene AM, von der Lippe G, Jensen G, Hampton JR. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian study of early thrombolysis (ASSET), Lancet. 1988;2:525-530.
2. Gruppo Italiano per Io Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1: 397-401.
3. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
4. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet. 1994; 343: 311-322.
5. Kleiman N, Terrin M, Mueller H, Chaitman B, Roberts R, Braunwald E, Knatterud G, Solomon R, McMahan R, the TIMI investigators. Mechanisms of early death despite thrombolytic therapy: Experience from the Thrombolysis in Myocardial Infarction phase II (TIMI) study. J Am Coll Cardiol. 1992;19:1129-1135.
6. Gotlieb AI, Havenith MG. In: Silver MS, ed. Cardiovascular Pathology. 2nd ed. New York: Churchill Livingstone; 1991:393-440.
7. Qayumi AK, Jamieson WRE. Pathophysiology of reperfusion injury in organ transplantation. In: Das DK, ed. Pathophysiology of Reperfusion Injury. Boca Raton, FL: CRC Press; 1993:325-362.
8. Holland CE, Olson RE. Prevention by hypothermia of paradoxical calcium necrosis in cardiac muscle. J Mol Cell Cardiol. 1975;7:917-725.
9. Fleckenstein A, Lossnitzer K, Pfennigsdork G, Brauer H. In: Myocardium Vessels Calcium: An Illustrated Synopsis of the Principle of Calcium Antagonism. Ludwigshafen, Munich: Ag Knoll; 1983.
10. Feher J, Cosmos G, Vereckei A, eds. Free Radical Reactions in Medicine. Berlin: Springer-Verlag; 1987: 24-56.
11. McCord JM, Fridovich I. Superoxide dismutases: A history. In: Michelson AM, McCord JM, Fridovich I, eds. Superoxide and Superoxide Dismutases. San Francisco: Academic Press; 1977:1-17.
12. Taylor AE, Matalon S, Ward PA, eds. Physiology of Oxygen Radicals. San Francisco: USA Waverly Press; 1986:120-133.
13. Hearse DJ, Manning AS, Downey JM, Yellon DM. Xanthine oxidase: A critical mediator of myocardial injury during ischemia and reperfusion. Acta Physiol Scand. 1986;548(suppl): 65-78.
14. Kozlov AV, Shinkarenko LI, Vladimirov IUA, Aziozova OA. The role of endogenous free iron in activating lipid peroxidation in ischemia. Biull Eksp Biol I Med. 1985;99: 65-78.
15. Meerson RZ, Kagan VE, Lozlov YP, Belkina LM, Arkhipenko YV. The role of lipid peroxidation in pathogenesis of ischemic damage and antioxidant protection of the heart. Basic Res Cardiol. 1982;77:465-485.
16. Torok B, Roth E, Zsoldos T, Tigyi A, Matkovics B, Szabo L. Lipid peroxidation in lung of rats exposed to hyperoxic, hypoxic and ischemic effects. Exp Pathol. 1986;29:221-226.
17. White BC, Krause GS, Aust DD, Eyster GE. Postischemic tissue injury by iron-mediated free radical lipid peroxidation. Ann Emerg Med. 1985;14:804-809.
18. Pober JS, Cotran RS. The role of endothelial cell in inflammation. Transplant. 1990;50: 537-544.
19. Brenner BM, Troy JL, Blatermann BJ. Endothelium-dependent vascular responses. Mediators and mechanisms. J Clin Invest 1989;84:1373-1378.
20. Camussi G, Brentjens JR. In: Snyder F, ed. Platelet-Activating Factor and Related Lipid Mediators. New York: Plenum Press; 1987:299.
21. Ontell SJ, Makowka L, Boccagni P, Starzl TE. The role of PAF and its antagonism in transplantation: Organ ischemia and preservation. In: Handley DA, Saunders RN, Houlihan WJ, Tomesch JC, eds. Platelet Activating Factor in Endotoxin and Immune Diseases. New York: Marcel Dekker; 1990:419.
22. Tsujimoto M, Toyama Y [cited in Baer E, Stanacev NZ]. Phosphonolipids. II: Synthesis of dialkyl L-alpha-glyceryl-(c-2 aminoethyl) phosphonates. J Biol Chem. 1965;240: 44-48.
23. Carter HE, Smith DB, Jones DN. A new ethanolamine-containing lipide from egg yolk. J Biol Chem. 1958;232: 681-694.
24. Renkonen O. Lecithins of glycerol ether character in normal human serum. Biochim Biophys Acta. 1962;59: 497-499.
25. Pietruzko R, Gray RE. The products of mild alkaline and mild acid hydrolysis of plasmalogens. Biochim Biophys Acta. 1962;56:232-239.
26. Muirhead EE, Rightsel WA, Leach BE, Byers LW, Pitcock VA, Brooks B. Reversal of hypertension by transplants and extracts of cultured renomedullary interstitial cells. Lab Invest. 1977;35:162-172.
27. Benveniste J, Henson PM, Cochrane CG. Leukocyte-dependent histamine release from rabbit platelets: The role of IgE, basophils, and a platelet-activating factor. J Exp Med. 1972;136: 1356-1377.
28. Benveniste J, Tence M, Varenne P, Bidault J, Boullet C, Polonsky J. Semi-synthesis and proposed structure of platelet-activating factor (PAF): PAF-acether an alkyl ether analog of lysophosphatidylcholine. CRC Acad Sci. 1979;289D:1937-2040.
29. Blank ML, Snyder F, Byers LW, Brooks B, Muirhead EE. Antihypertensive activity of an alkyl ether analog of phosphatidylcholine. Biochem Biophys Res Commun. 1979;90:1194-1200.
30. Demopoulos CA, Pinckard RN, Hanahan DJ. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (as a new class of lipid chemical mediators). J Biol Chem. 1979;254:9355-9358.
31. Polonsky J, Tence M, Varenne P, Das BP, Lunel J, Benveniste J. Release of 1-O-alkylglyceryl-3-phosphorylcholine, O-deacetyl platelet-activating factor, from leukocytes: Chemical ionization mass spectrometry of phospholipids. Proc Natl Acad Sci U S A. 1980;77:7019-7023.
32. Rabinovici R, Yue T-L, Feuerstein G. Platelet-activating factor in cardiovascular stress situations. Lipids. 1991;26: 1257-63.
33. Snyder F. Chemical and biochemical aspects of platelet activating factor: A novel class of acetylated ether-linked choline phospholipids. Med Res Rev. 1985;5:107-140.
34. Summers JB, Albert AH. Platelet activating factor antagonists. Adv Pharm. 1995;32:67-168.
35. Braquet P, Touqui L, Shen TY, Vargaftig BB. Perspectives in platelet-activating factor research. Pharmacol Rev. 1987;39:97-145.
36. Snyder F, Lee T-C, Blank ML The role of transacylases in the metabolism of arachidonate and platelet-activating factor. Prog Lipid Res. 1992;31:65-86.
37. Winkler JD, Chilton FH. The role of CoA-independent transacylases in the production of platelet-activating factor and the metabolism of arachidonate. Drug News Perspec. 1993;6:133-138.
38. Wykle RL, Malone B, Snyder F. Enzymatic synthesis of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine, a hypotensive and platelet-aggregating lipid. J Biol Chem. 1980; 255:10256-10260.
39. Woodard DS, Lee T-L, Snyder F. The final step in the de novo biosynthesis of platelet activating factor. J Biol Chem. 1987;262:2520-2527.
40. Lee T-L, Malone B, Snyder F. Formation of 1-alkyl-2-acetyl-sn-glycerols via the de novo biosynthetic pathway for platelet-activating factor. J Biol Chem. 1988;263:1755-1760.
41. Snyder F. Enzymatic pathways for platelet-activating factor, related alkyl glycerolipids and their precursors. In: Snyder F, ed. Platelet-Activating Factor and Related Lipid Mediators. New York: Plenum; 1987.
42. Smiley PL, Stremler KE, Prescott SM, Zimmerman GA, McIntyre TM. Oxidatively fragmented phosphatidylcholines activate human neutrophils through the receptor for platelet-activating factor. J Biol Chem. 1991;266: 11104-11110.
43. Tanaka T, Iimori M, Tsukatani H, Tokumura A. Platelet-aggregating effects of platelet-activating factor like phospholipids formed by oxidation of phosphatidylcholines containing an sn-2-polyunsaturated fatty acyl group. Biochim Biophys Acta. 1994;1210:202-208.
44. Lynch MJ, Grum CM, Gallagher KP, Boiling SF, Deeb GM, Morganroth ML. Xanthine oxidase inhibition attenuates ischemic reperfusion injury. J Surg Res. 1988;44:538-544.
45. Stewart AG, Dubbin PN, Harris T, Dusting GJ. Evidence for an intracellular action of PAF in bovine cultured aortic endothelial cells. Br J Pharmacol. 1989;96:503-505.
46. Albert DH, Snyder F. Biosynthesis of 1-alkyl-2 acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) from 1-alkyl-2-acyl-sn-glycero-3-phosphocholine by rat alveolar macrophages. J Biol Chem. 1983;258:97-102.
47. Pieroni G, Hanahan DJ. Metabolic behavior of acetyl glyceryl ether phosphorylcholine on interaction with rabbit platelets. Arch Biochem Biophys. 1983;224:485-493.
48. Blank ML, Lee T-C, Fitzgerald V, Snyder F. A specific hydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine hypotensive platelet activating lipid. J Biol Chem. 1981;256:175-178.
49. Kleiman NS, White HD, Ohman EM, Ross AM, Woodlief LH, Califf RM, Holmes DR, Bates E, Pfisterer M, Vahanian A, Topol EJ. Mortality within 24 hours of thrombolysis for myocardial infarction: The importance of early reperfusion. Circulation. 1994;90:2658-2665.
50. Kim YD, Danchak RM, Heim KF, Lees DE, Myers AK. Constriction of canine coronary arteries by platelet activating factor after brief ischemia. Prostaglandins. 1993;46:269-276.
51. Abraham E, Schoemaker WC, Bland RD, Cobo JC. Sequential cardiorespiratory patterns in septic shock. Crit Care Med. 1983;11:799-803.
52. Harlan JM, Winn RK. The role of phospholipase products in the pathogenesis of vascular injury in sepsis. In: Sande M, Root RR, eds. Septic Shock? Newer Concepts in the Pathophysiology and Treatment. New York: Churchill Livingstone, 1988:83-104.
53. Parker CW. Systemic Anaphylaxis. In: Parker CW, ed. Clinical Immunology. Philadelphia: WB Saunders; 1980: 1208-1218.
54. Smith PL, Kagey-Sobotka A, Bleecker ER, Traystman R, Kaplan AP, Gralnick H, Valentine MD, Permutt S, Lichtenstein LM. Physiologic manifestation of human anaphylaxis. J Clin Invest. 1980;66:1072-1080.
55. Bleecker ER, Lichtenstein LM. In: LM Lichtenstein, AS Fauci, eds. Current Therapy in Allergy and Immunology. St Louis: C.V. Mosby; 1983:78-83.
56. Laurindo FR, Goldstein RE, Davenport NJ, Ezra D, Feuerstein GZ. Mechanisms of hypotension produced by platelet-activating factor. J Appl Physiol. 1989;66:2681-2690.
57. Flores NA, Sheridan DJ. Electrophysiological and arrhythmogenic effects of platelet activating factor during normal perfusion, myocardial ischaemia and reperfusion in the guinea-pig. Br J Pharmacol. 1990;101:734-738.
58. Chakrabarty S, Thomas P, Sheridan DJ. Contribution of platelets and platelet-activating factor (PAF) to the arrhythmogenic, haemodynamic and necrotic effects of acute myocardial ischaemia. Eur Heart J. 1991;12:583-589.
59. Felix SB, Baumann G, Ahmad Z, Hashemi T, Niemczyk M, Berdel WE. Effects of platelet-activating factor on myocardial contraction and myocardial relaxation of isolated perfused guinea pig hearts. J Cardiovasc Pharmacol. 1990;16:750-756.
60. Stahl GL, Lefer DJ, Lefer AM. PAF-acether induced cardiac dysfunction in the isolated perfused guinea pig heart. Naunyn-Schmiedeberg's Arch Pharmacol. 1987; 336:459-463.
61. Sawa Y, Schaper J, Roth M, Nagasawa K, Ballagi G, Bleese N, Schaper W. Platelet-activating factor plays an important role in reperfusion injury in myocardium. J Thorac Cardiovasc Surg. 1994;108:953-959.
62. Qayumi AK, English JC, Godin DV, Ansley DM, Loucks EB, Lee JU, Kim CW. The role of platelet activating factor in the pathophysiology of regional myocardial ischemia-reperfusion injury. Ann Thorac Surg. In press.
63. Ko W, Lang D, Hawes AS, Zelano JA, Isom OW, Krieger K. Platelet-activating factor antagonism attenuates platelet and neutrophil activation and reduces myocardial injury during coronary reperfusion. J Surg Res. 1993;55: 504-515.
64. Qayumi AK, Godin DV, English JC, Loucks EB, Lim SP, Al Mahmeed T, Horley KJ, Gul S. Therapeutic potential of PAF antagonist in the management of myocardial infarction. Ann Thor Surg. Submitted.
65. Katoh S, Toyama J, Kodama I, Koike A, Toshio A. Role of platelet activating factor in ischaemia-reperfusion injury of isolated rabbit hearts: Protective effect of a specific platelet activating factor antagonist, TCV-309. Cardiovasc Res. 1993;27:1430-1434.
66. Vleeming W, Wemer J, Porsius AJ. Modulation of antigen- and ischemia-induced effects by the platelet-activating factor antagonist WEB-2086 in isolated sensitized rat hearts. J Cardiovasc Pharmacol. 1992;20:790-799.
67. Koltai M, Tosaki A, Hosford D, Braquet P. Ginkolide B protects isolated hearts against arrhythmias induced by ischemia but not reperfusion. Eur J Pharmacol. 1989;164: 293-302.
68. Koltai M, Tosaki A, Hosford D, Esanu A, Braquet P. Effect of BN 50639, a new platelet activating factor antagonist, on ischaemia induced ventricular arrhythmias in isolated working rat hearts. Cardiovasc Res. 1991;25: 391-397.
69. Robertson DA, Genovese A, Levi R. Negative inotropic effect of platelet-activating factor on human myocardium: A pharmacological study. J Pharmacol Exp Ther. 1987;243:834-839.
70. Camussi G, Alloatti G, Montrucchio G, Meda M, Emanuelli G. Effect of platelet activating factor on guinea-pig papillary muscle. Experientia. 1984;40:697-699.
71. Robertson DA, Wang D-Y, Lee CO, Levi R. Negative inotropic effect of platelet-activating factor: Association with a decrease in intracellular sodium activity. J Pharmacol Exper Ther. 1988;245:124-128.
72. Delbridge LM, Stewart AG, Goulter CM, Morgan TO, Harris PJ. Platelet-activating factor and WEB-2086 directly modulate rat cardiomyocyte contractility. J Mol Cell Cardiol. 1994; 26:185-193.
73. Janero DR, Burghardt C. Production and release of platelet-activating factor by the injured heart-muscle cell (cardiomyocyte). Res Commun Chem Pathol Pharmacol. 1990;60:201-218.
74. Sugimoto T, Tsuchimochi HH, McGregor CGA, Mutoh H, Shimizu T, Kurachi Y. Molecular cloning and characterization of the platelet-activating factor receptor gene expressed in the human heart. Biochem Biophys Res Commun. 1992;189:617-624.
75. Schwinger RHG, Bohm M, Rosee KL, Erdmann E. Existence of PAF receptors in human platelets and human lung tissue but not in the human myocardium. Am Heart J. 1992;124: 320-330.
76. Piper PJ, Stewart AG. Coronary vasoconstriction in the rat, isolated perfused heart induced by platelet-activating factor is mediated by leukotriene C4. Br J Pharmacol. 1986;88:595-605.
77. Piper PJ, Stewart AG. Antagonism of vasoconstriction induced by platelet-activating factor in guinea-pig perfused hearts by selective platelet-activating factor receptor antagonists. Br J Pharmacol. 1987;90:771-783.
78. Hu W, Man RYK. Interaction of vasoactive substances released by platelet-activating factor in the rat perfused heart. Br J Pharmacol. 1991;104:933-937.
79. Benveniste J, Boullet C, Brink C, Labat C. The actions of PAF-acether (platelet-activating factor) on guinea pig isolated heart preparations. Br J Pharmacol. 1983;80: 81-83.
80. Saeke S, Masugi F, Ogihara T, Otsuka A, Kumahara Y, Watanabe K, Tamure K, Akashi A, Kumagai A. Effects of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet activating factor) on cardiac function in perfused guinea-pig heart. Life Sci. 1985;37:325-329.
81. Feuerstein GZ, Boyd L, Ezra D, Goldstein R. Effect of platelet activating factor on the coronary circulation of the domestic pig. J Am Physiol. 1984;246:H466-H471.
82. Vleeming W, Wemer J, Porsius AJ. Modulation of antigen- and ischemia-induced effects by the platelet-activating factor antagonist WEB-2086 in isolated sensitized rat hearts. J Cardiovasc Pharmacol. 1992;20:790-799.
83. Bussolino F, Camussi G. Platelet activating factor produced by endothelial cells: A molecule with autocrine and paracrine properties. Eur J Biochem. 1995;229:327-337.
84. Camussi G, Tetta C, Bussolino F, Baflioni C. Synthesis and release of platelet activating factor is inhibited by plasma a1 antichymotripsin and is stimulated by proteinases. J Exp Med. 1988;168:1293-1316.
85. Sun DX, Rui YC, Zeng GQ, Zhu J, Shen YA. Specific binding sites of platelet activating factor in the intact bovine cerebral microvascular endothelial cells and antagonism of drugs. Acta Pharm Sinica. 1992;57:326-329.
86. Korth R, Hirafuji M, Keraly CL, Delatuer D, Bidault J, Benveniste J. Interaction of antagonist WEB 2086 and its hetrazepine analogue with human platelets and endothelial cells. Biochem Pharmacol. 1989;44:223-229.
87. Wainwright CL, Parratt JR, Bigaud M. The effects of PAF antagonists on ischaemia and reperfusion arrhythmias and ischemia-induced platelet aggregation. Biomed Biochim Acta. 1988;10/11:S224-S227.
88. Auchampach JA, Maruyama M, Cavero I, Gross GJ. Blocking platelet activating factor receptors with RP 59227 decreases myocardial infarct size and the incidence of ventricular fibrillation. J Mol Cell Cardiol. 1991;23:S52.
89. Chakrabarty S, Thomas P, Sheridan DJ. Contribution of platelets and platelet-activating factor (PAF) to the arrhythmogenic, haemodynamic and necrotic effects of acute myocardial ischaemia. Eur Heart J. 1991;12:583-589.
90. Montrucchio G, Alloatti G, Mariano F, De Paulis R, Comino A, Emanuelli G, Camussi G. Role of platelet-activating factor in the reperfusion injury of rabbit ischemic heart. Am J Pathol. 1990;137:71-83.
91. Wainwright CL, Parratt JR, Bigaud M. The effects of PAF antagonists on arrhythmias and platelets during acute myocardial ischaemia and reperfusion. Eur Heart J. 1989;10:235-243.
92. Leong LL, Sturm MJ, Papadimitriou JM, Stephens CJ. The effects of a PAF antagonist on ischemic myocardial damage and arrhythmia in the dog. J Mol Cell Cardiol. 1992;24:641-649.
93. Black SC, Driscoll EM, Lucchesi BR. Inhibition of platelet-activating factor fails to limit ischemia and reperfusion-induced myocardial damage. J Cardiovasc Pharmacol. 1992;20: 997-1005.
94. Ma X-L, Weyrich AS, Krantz S, Lefer A. Mechanisms of the cardioprotective actions of WEB-2170, bepafant, a platelet activating factor antagonist, in myocardial ischemia and reperfusion. J Pharmacol Exp Ther. 1992;260: 1229-1236.
95. Stewart AG, Dusting GJ. Characterization of receptors for platelet-activating factor on platelets, polymorphonuclear leukocytes and macrophages. Br J Pharmacol. 1988;94:1225-1233.
96. Marcheselli VL, Rossowska MJ, Domingo MT, Braquet P, Bazan NG. Distinct platelet-activating factor binding sites in synaptic endings and in intracellular membranes of rat cerebral cortex. J Biol Chem. 1990;265:9140-9145.
97. Houlihan WJ. Platelet-activating factor antagonists. In: Handley DA, Saunders RN, Houlihan WJ, Tomesch JC, eds. Platelet-Activating Factor in Endotoxin and Immune Diseases. New York: Marcel Dekker; 1990:31-76.
98. Terashita Z, Tsushima S, Yoshioka Y, Nomura H, Inada Y, Nishikawa K. CV-3988. A specific antagonist of platelet-activating factor (PAF). Life Sci. 1983;32:1975-1982.
99. 3H]-platelet activating factor (PAF) to the platelet. Biochem Pharmacol. 1985;34:1491-1495.
100. Robertson DN, Smith GM. CV-3988 inhibits in vivo platelet aggregation induced by PAF-acether and collagen. Eur J Pharmacol. 1986;123:91-97
101. Nunez D, Chignard M, Korth R, LeCouedic JP, Norel X, Spinnewyn B, Braquet P, Benveniste J. Specific inhibition of PAF-acether induced platelet activating by BN 502021 and comparison with the PAF-acether inhibitors kadsurenone and CV-3988. Eur J Pharmacol. 1986;123:197-205.
102. Oura Y, Sakiyama N, Ueshima R, Higuchi M, Kakishita E, Nagai K. Effect of platelet activating factor on the collagen-induced platelet aggregation in whole blood. Thromb Haemost. 1987;58:185.
103. Terashita Z, Imura Y, Shino A, Nishikawa K. A lethal role of platelet activating factor in anaphylactic shock in mice. J Pharmacol Exp Ther. 1987;243:378-383.
104. Toth PD, Mikulaschek AW. Effects of a platelet-activating factor antagonist, CV-3988 on different shock models in the rat. Circ Shock. 1986;20:193-203.
105. 2 and a platelet-activating antagonist. Can J Physiol Pharmacol. 1987; 65:1428-1432.
106. Satoh H, Adachi M, Imai T, Okazawa A, Kamiya T, Nishikata N, Kobayashi H, Takahashi T, Yamaguchi H. The effects of specific antagonist of PAF (CV-3988) on airway hyperresponsiveness induced by ozone exposure in beagles. Aerugi. 1987;36:306-312.
107. Lang M, Hansen D, Hahn HL Effects of PAF-antagonist CV-3988 on PAF-induced changes in mucous secretions and in the respiratory and circulatory variables in ferrets. Agents Actions. 1987;21(suppl):245-252.
108. Arnout J, van Hecken A, Depeleire I, Miyamoto Y, Holmes I, Deschepper P, Vermylen J. Effectiveness and tolerability of CV-3988, a selective PAF antagonist, after intravenous administration to man. Br J Clin Pharmacol. 1988;25:445-451.
109. Takatani M, Maezaki N, Imura Y, Terashita Z-I, Nishikawa K, Tsushima S. Platelet activating (PAF) antagonists; Development of a highly potent PAF antagonist, TCV-309. In: Samuelsson B, ed. Advances in Prostaglandin, Thromboxane and Leukotriene Research. New York: Raven Press; 1990:943-946.
110. Terashita Z-I, Imura Y, Takatani M, Tsushima S, Nishikawa K. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo. J Pharmacol Exp Ther. 1987;242:263-268.
111. Terashita Z-I, Takatani M, Nishikawa K. Pharmacological profile of TCV-309: A potent PAF antagonist. J Lipid Mediat. 1992;5:83-185.
112. Terashita Z-I, Kawamura M, Takatani M, Tsushima S, Imura Y, Nishikawa K. The beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents. J Pharmacol Exp Ther. 1992;260:748-755.
113. Prous J, Mealy N, Castaner J. TCV-309. Drugs Fut. 1993;18:721-725.
114. Handley, DA. Development and therapeutic indications for PAF antagonists. Drugs Fut 1988;13:137-152.
115. Shen TY, Yang SS, Hwang S-B. Indene derivatives useful as PAF-antagonists. Eur Pat Appl. 1985;142:801(May 29).
116. Hwang S-B, Chang MN, Garcia ML, Han QQ, Huang L, King VF. L-652,469 - a dual receptor antagonist of platelet activating factor and dihydropyridines from Tussilago farfara L. Eur J Pharmacol. 1987;141:269-281.
117. Shen TY, Hwang S-B, Chang MN, Doebber TW, Lam M-H, Wu MS, Wang X, Han GQ, Li RZ. Characterization of a platelet-activating factor receptor antagonist isolated from heifenteng (Piper futokadsurae): Specific inhibition in vitro and in vivo platelet-activating factor-induced effects. Proc Natl Acad Sci U S A. 1985;82:672-676.
118. Shen TY, Hussaini IM. Kadsurenone and other related lignans as antagonists of PAF receptor. In: Murphy RC, Fitzpatrick FA, eds. Methods in Enzymology. San Diego: Academic Press; 1990:446-454.
119. Braquet P, unpublished data [cited in Braquet P, Toqui L, Shen TY, Vargaftig BB]. Perspectives in platelet-activating factor research. Pharmacol Rev. 1987;39:97-145.
120. Okamoto M, Yoshida K, Uchida I, Nishikawa M, Koshaka M, Aoki H. Studies on platelet activating factor (PAF) antagonists from microbial products: I. Bis-dethiobis(methylthio)gliotoxin and its derivatives. Chem Pharm Bull. 1986;34:340-344.
121. Kirby GW, Robins DJ, Sefton MA, Talekar RR. Biosynthesis of bisbethiobis(methylthio)gliotoxin, a new metabolite of Gliocladium deliquescens. J Chem Soc Perkins Trans. 1980;1: 119.
122. Casals-Stenzel J, Weber KH. Triazolobenzodiazepines: Dissociation of their PAF (platelet activating factor) antagonists and CNS activity. J Pharmacol. 1987;90:139-146.
123. Casals-Stenzel J, Muacevic G, Weber K-H. Pharmacological actions of WEB-2086, a new specific antagonist of platelet activating factor. J Pharmacol Exp Ther. 1987; 241:974-981.
124. Casals-Stenzel J, Weber KH. Triazoloidiazepines: disassociation of their PAF (platelet-activating factor) antagonistic and CNS acivity. Brit J Pharmacol. 1987;90:139-146.
125. Heuer H, Casals-Stenzel J, Muacevic G, Stransky W, Weber K-H. Effect of the PAF-antagonists WEB 2170 and STY 2108, two hetrazepines with PAF-antagonistic activity on PAF-induced changes in vitro and in vivo. In: Recent Advances in Platelet-Activating Factor. Brisbane, Australia: September 3-5, abstract 4; 1987.
126. Braquet P. Treatment or prevention of PAF-acether disorders provoked by a new series of highly specific inhibitors. Brit. Pat. 8418424, July 19, 1984; Belg Pat. 901,915; see Chem Abstr. 1985;103:189808d.
127. Braquet P, Drieu P, Etienne A. Le Ginkgolide B (BN 52021): Un puissant inhibiteur du PAF-acether isole du Ginkgo biloba L. Actual Chim Ther (Paris). 1985;13:237-254.
128. Dupont L, Germain G, Dideberg O. Crystal and molecular structure of BN 52021, a PAF-acether antagonist, compared with the conformation of kadsurenone and related compounds. Pharmacol Res Commun. 1986;18: 25-32.
129. 2O, a highly specific PAF-acether receptor antagonist isolated from Ginkgo biloba L. Acta Cristallogr. 1986;C42:1759-1762.
130. Desquand S, Touvay C, Tandon J, Lagente V, Maridonneau-Parini I, Lefort J, Etienne A, Braquet P, Vergaftig BB. Interference of Ginkgolide B (BN 52021) with the bronchopulmonary effects of PAF-acether in the guinea pig. Eur J Pharmacol. 1986;127:83-95.
131. Sanchez-Crespo M, Fernandez-Gallardo S, Nieto ML, Barones J, Braquet P. Inhibition of the vascular action of IgG aggregates by BN 52021, a highly specific antago-nist of PAF-acether. Immunopharmacology 1985;10: 69-75.
132. Weber KH, Heuer H, Birke F, Bechtel W, Harreus A, Stransky W, Walther G, Casals-Stenzel J. 2,2-Annelated thienotriazolo-1,4-diazepines as PAF antagonists (and its structure-activity relationship). In: Recent Advances in Platelet Activating Factor. Brisbane, Australia: September 3-5, abstract 15; 1987.
133. Wallace JL, Steel G, Whittle BJR, Lagente V, Vargaftig BB. Evidence for platelet activating factor (PAF) as a mediator of endotoxin-induced gastrointestinal damage in the rat: Effects of three PAF antagonists. Gastroenterology 1987;93:765-773.
134. Droy-Lefaix MT, Drouet Y, Geraud G, Braquet P. The amplicative role of PAF-acether in the oxidative stress following the reperfusion of ischemic stomach. Bas Life Sci. 1988;49: 887-890.
135. Verbey NLJ, van Delft J, Oosterhuis JA, Braquet P, van Haeringen NJ. Interference of a PAF-acether antagonist, BN-52021, in corneal and iris models of eye disease. In: Recent Advances in Platelet Activating Factor. Brisbane, Australia: September 3-5, abstract 6; 1987.
136. Touvay C, Vilain B, Menica-Huerta JM, Braquet P. Endotoxin-induced inhibition of beta-adrenergic relaxation in guinea-pig lung: Effects of BN 52021. In: Recent Advances in Platelet Activating Factor. Brisbane, Australia: September 3-5, abstract 27; 1987.
137. Adnot S, Lefort J, Lagente V, Braquet P, Vargaftig BB. Interference of BN 52021, a PAF-acether antagonist, with endotoxin induced hypotension in the guinea pig. Pharmacol Res Commun. 1986;18:197-200.
138. Adnot S, Lefort J, Braquet P, Vargaftig BB. Interference of the PAF-acether antagonist BN 52021 with endotoxin-induced hypotension in the guinea pig. Prostaglandins. 1986;32:791-802.
139. Etienne A, Hecquet F, Soulard C, Spinnewyn B, Clostre F, Braquet P. In vivo inhibition of protein leakage and Salmonella enteritidis-induced mortality in the rat by a specific PAF-acether antagonist: BN 52021. Agents Actions. 1985;17:368-370.
140. Trebieb HA, Calixto JB. Further evidences for the mechanism involved in Bothrops jararaca venom-induced oedema in the rat paw. In: Franco Brazilian Symposium on Chemistry and Pharmacology of Natural Products in Inflammation Allergy and Thrombosis. Rio de Janeiro, November 16-19, 1986.
141. Lopez-Farre A, Gomez-Garre D, Bernabeu F, Ramon y Cajal S, Lopez-Novoa JM. Platelet-activating factor mediates glycerol-induced acute renal failure in rats. Clin Sci. 1990;79: 551-558.
142. Lagente V, Touvay C, Randon J, Desquand S, Cirino M, Villain B. Interference of the PAF-acether antagonist BN 52021 with passive anaphylaxis in the guinea pig. Prostaglandins. 1987;33:256-274.
143. Braquet P, Etienne A, Touvay C, Bourgain RH, Lefort J, Vargaftig BB. Involvement of platelet activating factor in respiratory anaphylaxis, demonstrated by PAF-acether inhibitor BN 52021 (letter). Lancet. 1985;1:1501.
144. Lellouch-Tubiana A, Lefort J, Simon M-T, Pfister A, DaLage C, Vargaftig BB. Comparison of the eosinophilotactic effect of PAF-acether and antigen in vivo: The role of PAF-acether antagonists and platelets. In: The Role of Platelet Activating Factor in the Immune Response. Paris: June 25-26, 1987:41 (Abst.).
145. Coyle AJ, Robertson DN, Page CP. The role of PAF in antigen-induced eosinophil accumulation in the lung. In: The Role of Platelet Activating Factor in the Immune Response. Paris: June 25-26; 1987:42 (Abst.).
146. Koltai M, Lepran I, Szekeres L, Viossat I, Chabrier PE, Braquet P. Effect of BN 52021, a specific PAF-acether antagonist, on cardiac anaphylaxis in Langendorff hearts isolated from passively sensitized guinea pigs. Eur J Pharmacol. 1986;130:133-136.
147. Foegh ML, Bijan S, Khirbadi BS, Rowles JR, Ramwell PW. Synergistic effect of a PAF antagonist with azathioprine and cyclosprin in allograft survival. In: Winslow CM, Lee ML, eds. New Horizons in Platelet-Activating Factor Research. New York: John Wiley; 1987:343-346.
148. Martin-Mondiere C, David P, Sigaux N, Leandri J, Loisnace D. Action of BN 52021, a specific platelet activating factor (PAF-acether) antagonist, on microporous Polyurethane prothesis implanted in the pig. In: European Society of Surgical Research Annual Meeting Aarhus, The Netherlands, June, 1987.
149. Pirotzky E, Colliez P, Guilmard C, Schaeverbeke J, Mencia-Huerta JM, Braquet P. Protection of cyclosporin-induced nephrotoxicity by BN 52063 in the rat. In The Role Platelet Activating Factor in the Immune Response. Paris: June 25-26; 1987:64 (Abst.).
150. Hwang S-B, Cheah MJ, Lee C-SC, Shen TY. Effect of nonsteroid antiinflammatory drugs on the drugs on the specific binding of platelet factor to membrane preparation of rabbit platelets. Thromb Res. 1984;34:519-531.
151. Bussolino F, Camussi G. Effect of prostacyclin and platelet-activating factor induced rabbit platelet aggregation. Prostaglandins. 1980;20:781-791.
152. 2). Agents Actions. 1981;11: 550-553.
153. 2) on neutropenia induced by intravenous injection of platelet-activating factor (PAF) in the rabbit. Prostaglandins. 1983;25:343-351.
154. Grandel KE, Farr RS, Wanderer AA, Eisenstadt TC, Wasserman SW. Association of platelet-activating factor with primary acquired cold urticaria. N Engl J Med. 1985;313:405-409.
155. MacIntyre DE, Shaw AM. Phospholipid-induced human platelet activation: Effects of calcium blockers and calcium chelators. Thromb Res. 1983;31:833-844.
156. Khan SN, Lane PA, Smith AD. Desaggregation of PAF-acether aggregated platelets by verapamil and TMB-8 with reversal of phosphorylation of 40K and 20 K proteins. Eur J Pharmacol. 1985;107:189-198.
157. Keraly CL, Delautier D, Delabassee D, Chignard M, Benveniste J. Inhibition by ticlopidine of PAF-acether-induced in vitro aggregation of rabbit and human platelets. Thromb Res. 1984;34:463-471.
158. Kelefiotis D, Lanara E, Lemionas CV, Siafaka A, Marvis M, Demopoulos CA. Inhibition of the in vivo effects of alkyl acetyl glyceryl phosphorylcholine (AGEPC) on mice by digoxin. In: First International Conference on Platelet Activating Factor and Structurally Related Ether Lipids. Paris: June 26-29; 1983:57, 101 (Abst).
159. Shen TY, Hwang S-B. The chemical and biological properties of PAF agonists, antagonists, and biosynthetic inhibitors. In: Snyder F, ed. Platelet-Activating Factor and Related Lipid Mediators. New York: Plenum; 1987:66-87.
160. Qayumi AK, Jamieson WRE, Poostizadeh A. Effects of platelet-activating antagonist CV-3988 in preservation of heart and lung for transplantation. Ann Thor Surg. 1991;52:1026-1032.
161. Qayumi AK, Jamieson WRE, Poostizadeh A, Germann E, Gillespie KD. Comparison of new iron chelating agents in the prevention of ischemia/reperfusion injury: A swine model of heart-lung transplantation. J Invest Surg. 1992;5:115-127.
162. Qayumi AK, English J, Feeley EJE, Poostizadeh A, Gillespie K, Nash D. A new platelet activating antagonist, CV-6209 in the management of ischemia-reperfusion injury in a swine model of heart-lung transplantation. Cardiovasc Drug. In press.
163. Qayumi AK, English JE, Fradet G, Ansley DM, Pearson B, Nikbakht-Sangari M, Sammartino C. Extended (20 hours) of lung preservation using PAF-antagonist TCV-309 in combination with prostaglandin PGE. J Heart Lung Transplant. 1997;16:946-955.
164. Qayumi AK, Nikbakht-Sangari M, Godin DV, English JC, Horley KJ, Keown PA, Lim SP, Ansley DM, Koehle MS. The relationship of ischemia reperfusion injury